However, future in vitro and in vivo studies are warranted to evaluate the physicochemical properties, pharmacokinetics, and LAT1 inhibitory activity of THC-di-Phe before translating it to clinical trials as a novel therapeutic lead for glioma. This evidence concerns the gene SLC7A5 and central nervous system cancer.